[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
May 4, 2005

Drug-Eluting Stents in Acute Myocardial InfarctionIs Science Catching Up With Practice?

Author Affiliations
 

Author Affiliations: Division of Cardiology, University of North Carolina at Chapel Hill (Drs Cohen and Ohman)

JAMA. 2005;293(17):2154-2156. doi:10.1001/jama.293.17.2154

In the last 3 to 4 years, the use of drug-eluting stents in clinical practice has revolutionized interventional cardiology. Two pivotal trials using sirolimus- and paclitaxel-eluting stents and reporting previously unheard-of single-digit restenosis rates1,2 heralded a new era for interventional cardiology, suggesting that the most vexing problem for intervention, namely, restenosis, had finally been tackled. These 2 trials predominantly studied patients undergoing elective procedures and found target-lesion revascularization rates of approximately 3% to 4% and postprocedure myocardial infarction rates that ranged from 2.8% to 3.5%.

First Page Preview View Large
First page PDF preview
First page PDF preview
×